Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-8846

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-8846). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298846)

Label for Rivastigmine Transdermal System 13.3 mg/24 hours extended release patch by Bryant Ranch Prepack. The label indicates each 15 cm² patch contains 27 mg Rivastigmine to deliver 13.3 mg over 24 hours, with storage and usage instructions. The package contains 30 systems and is for transdermal use only.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure of Rivastigmine, showing its molecular framework with nitrogen, oxygen, and methyl groups attached to a benzene ring, consistent with its identification as the active ingredient in Rivastigmine Transdermal System.*

FDA Label Image

Figure 1 (Rivastigmine 02)

An illustration showing a detailed cross-sectional view of the rivastigmine transdermal patch layers, labeled as Layer 1 through Layer 4. The image highlights two dimples on the patch surface, indicated by arrows. It visually explains the patch structure and its textured areas.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A line graph depicting rivastigmine concentration (ng/mL) over time (hours) for three dosage strengths of Rivastigmine Transdermal System (4.6 mg/24h, 9.5 mg/24h, 13.3 mg/24h). The graph shows concentration levels increasing and then declining over 24 hours, with different lines representing each dose and corresponding sample sizes noted in the legend.*

FDA Label Image

Figure 3 (Rivastigmine 04)

A line graph depicting clinical change over 24 weeks during treatment with Rivastigmine Transdermal System at doses 17.4 mg/24 hours and 9.5 mg/24 hours, capsules 6 mg BID, and placebo. The y-axis shows least square means change from baseline ADAS-cog rating indicating clinical improvement or decline, while the x-axis shows weeks during treatment (0,16,24). The 17.4 mg/24 hour dose shows greatest clinical improvement.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A bar chart showing the percentage of patients by ADCS-CGIC rating categories from markedly improved to markedly worse. The data compares four groups: 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo, illustrating patient response distribution across these treatment arms.*

FDA Label Image

Figure 5 (Rivastigmine 06)

A line graph showing the ADCS-IADL change from baseline over 52 weeks comparing two doses of Rivastigmine Transdermal System: 13.3 mg/24hr and 9.5 mg/24hr. The y-axis measures change from baseline with clinical improvement at the top and clinical decline at the bottom. The 13.3 mg/24hr dose shows a slower decline compared to 9.5 mg/24hr over time.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A line graph depicting the ADAS-Cog change from baseline (LS means and SEM) over weeks of treatment for Rivastigmine Transdermal System at doses of 9.5 mg/24 hr and 13.3 mg/24 hr. The vertical axis shows ADAS-Cog score change, ranging from -3 (clinical improvement) to 6 (clinical decline). Two lines illustrate cognitive changes over 48 weeks, with error bars indicating variability.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph comparing LS mean changes over 24 weeks for Rivastigmine Transdermal System at two patch sizes: 15 cm² (solid line with circles) and 5 cm² (dashed line with triangles). The vertical axis shows LS mean change ± standard error, indicating clinical improvement or decline, while the horizontal axis represents weeks of treatment. Statistical significance is noted for weeks 16 and 24 in the larger patch group.*

FDA Label Image

Figure 8 (Rivastigmine 09)

A line graph comparing the least squares mean change with standard error (LS Mean Change +/- STE) over 24 weeks of treatment for two strengths of Rivastigmine Transdermal System patches: 15 cm² and 5 cm². The x-axis represents weeks of treatment, and the y-axis indicates LS mean change with clinical improvement and decline marked. Statistical significance values at weeks 16 and 24 are shown, highlighting differences between the two patch sizes.*

FDA Label Image

Figure A (Rivastigmine 10)

An instructional diagram showing components of the Rivastigmine Transdermal System patch. It depicts a pouch labeled Rivastigmine Transdermal System, the patch with protective liners, and the adhesive side containing the medicine with an outside backing. Arrows indicate how the protective liners are positioned and highlight the adhesive with medicine.*

FDA Label Image

Figure B (Rivastigmine 11)

Instructional diagram showing recommended application sites for the Rivastigmine Transdermal System 13.3 mg/24h patch. Illustrated body silhouettes indicate patch placement options on the left or right upper arm, side of the chest, upper back, or lower back areas.*

FDA Label Image

Figure C (Rivastigmine 12)

An instructional illustration showing a hand holding a Rivastigmine Transdermal System patch packet and preparing to cut it open with scissors. The packet is labeled with the product name and usage instructions for the transdermal system.*

FDA Label Image

Figure D (Rivastigmine 13)

An instructional illustration showing hands peeling protective liners from the sticky surface of a Rivastigmine Transdermal System patch. The image highlights how to remove the liners to expose the adhesive side of the extended release transdermal patch for application.*

FDA Label Image

Figure E (Rivastigmine 14)

An instructional illustration showing the application of the Rivastigmine Transdermal System patch to the upper back of a person. One hand is placing the patch on the skin while the other hand is pressing it down to adhere it properly.*

FDA Label Image

Figure F (Rivastigmine 15)

An instructional illustration showing a human upper back and a hand, demonstrating the application of a transdermal patch. The image likely relates to proper placement of the Rivastigmine Transdermal System patch on the skin.*

FDA Label Image

Figure G (Rivastigmine 16)

An illustration showing the application of a Rivastigmine Transdermal System patch on the upper chest area. One hand holds the patch, while the other presses it onto the skin, demonstrating proper placement and adherence technique for the transdermal system.*

FDA Label Image

Figure H (Rivastigmine 17)

Instructional illustration for disposal of the Rivastigmine Transdermal System 13.3 mg/24h extended release patch. The three-panel diagram shows folding the sticky sides of the patch together, placing the folded patch into an empty pouch, and then discarding the pouch into a trash bin, with a reminder to keep it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.